Results 1 to 10 of about 76,618 (225)

A randomized controlled trial of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders

open access: yesTaiwanese Journal of Obstetrics & Gynecology, 2019
Objective: To evaluate the effectiveness of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders. Materials and methods: A randomized controlled trial in patients with refractory innate immune RSA was ...
Jinhua Fu, Lin Li, Lijuan Qi, Long Zhao
doaj   +1 more source

Etanercept therapy in rheumatoid arthritis: Efficacy and safety [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2013
Introduction. Etanercept, tumor necrosis factor (TNFα) antagonist, lowers the disease activity level in patients with rheumatoid arthritis (RA), reduces joint destruction saving physical functions and improving life quality. Objective. The aim of this
Ilić Tatjana   +4 more
doaj   +1 more source

Myelodysplasia in a psoriasis patient receiving etanercept : Cause or coincidence? [PDF]

open access: yes, 2018
Peer reviewedFinal Accepted ...
Ayoub, Othman Hadi   +3 more
core   +3 more sources

Treatment recommendations for psoriatic arthritis [PDF]

open access: yes, 2008
Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.
Ritchlin, CT   +15 more
core   +1 more source

SUCCESSFUL USE OF ETANERCEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITH AN OVERVIEW OF THE PREDICTORS OF A GOOD RESPONSE TO ONGOING THERAPY

open access: yesВопросы современной педиатрии, 2017
The  article  presents  a case  of  polyarticular  juvenile  idiopathic  arthritis  resistant  to  methotrexate  therapy  and  nonsteroidal  antiinflammatory drugs.  The child was prescribed  a tumor necrosis  factor   inhibitor etanercept  at a dose  of
Anna V. Karaseva   +2 more
doaj   +1 more source

Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]

open access: yes, 2018
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal   +8 more
core   +2 more sources

Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study

open access: yesJournal of Dermatological Treatment
Background The advent of biosimilars may increase the frequency of dose escalation with biologics in psoriasis.Objective To explore the frequency and outcomes of dose escalation with adalimumab etanercept, and ustekinumab.Methods Data were extracted from
Axel Svedbom   +4 more
doaj   +1 more source

Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans [PDF]

open access: yes, 2016
Preclinical studies demonstrate that pro-inflammatory cytokines increase serotonin transporter availability and function, leading to depressive symptoms in rodent models.
Burden, A. David   +10 more
core   +1 more source

The immune response mediator genes polymorphic variants as predictors of the etanercept efficacy in juvenile idiopathic arthritis

open access: yesRussian Open Medical Journal, 2018
Objective ― The aim of the study was to investigate the relationship of the alleles and genotypes of the immune response mediator genes polymorphic loci (rs1800629, rs909253, rs16944, rs6822844, rs2104286, rs1800795, rs1800872, rs3087243, rs755622 ...
Liliia Sh. Nazarova   +4 more
doaj   +1 more source

New insights into the impact of neuro-inflammation in rheumatoid arthritis. [PDF]

open access: yes, 2014
Rheumatoid arthritis (RA) is considered to be, in many respects, an archetypal autoimmune disease that causes activation of pro-inflammatory pathways resulting in joint and systemic inflammation.
Akasbi   +102 more
core   +2 more sources

Home - About - Disclaimer - Privacy